Replies to post #33078 on Endonovo Therapeutics Inc (ENDV)

[retired early]

Number of employees: 0 (2022)
Subsidiaries: IP Resources International Inc., WeHealAnimals, Inc., The Aviva Companies Corporation
Disclaimer
Financials
Quarterly financials
(USD) Jun 2023 Y/Y
Revenue 45.2K 6853.85%
Net income 2.06M 181.69%
Diluted EPS -0.01 50%
Net profit margin 4,565.62% 101.17%

Not bad for zero employees :) It's an ATM folks.

[Craig305]

You were not wrong about the compensation.
Per the offering details just released......how can he justify such large compensation expense when absolutely "nothing" happened in 2022.
I suppose Ira received a nice bonus to join ENDV late in 2022.

Our operating expenses increased by $1,105,038 or 48.4% to $3,389,705 in 2022 compared to $2,284,667 in 2021. The operating expenses were comprised primarily of consulting fees, professional fees, and stock-based compensation. This change was due primarily to an increase in stock-based compensation of approximately $1.2 million.